{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:13:03Z","timestamp":1787242383855,"version":"build-2736575974"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,4]],"date-time":"2020-07-04T00:00:00Z","timestamp":1593820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,4]],"date-time":"2020-07-04T00:00:00Z","timestamp":1593820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s11657-020-00761-0","type":"journal-article","created":{"date-parts":[[2020,7,4]],"date-time":"2020-07-04T13:02:43Z","timestamp":1593867763000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Therapeutic approach and management algorithms in medication-related osteonecrosis of the jaw (MONJ): recommendations of a multidisciplinary group of experts"],"prefix":"10.1007","volume":"15","author":[{"given":"Monique","family":"Chalem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6190-6805","authenticated-orcid":false,"given":"Adriana","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Karina","family":"Sarmiento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyanira","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Olarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Pinilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Paz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Casas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Paula","family":"Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edna","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,4]]},"reference":[{"issue":"1","key":"761_CR1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0002-9343(91)90512-V","volume":"90","author":"Consensus Development Conference","year":"1991","unstructured":"Consensus Development Conference (1991) Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 90(1):107\u2013110","journal-title":"Am J Med"},{"issue":"3","key":"761_CR2","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jama.285.3.320","volume":"285","author":"R Lindsay","year":"2001","unstructured":"Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB et al (2001) Risk of new vertebral fracture in the year following a fracture. JAMA. 285(3):320\u2013323","journal-title":"JAMA."},{"issue":"2A","key":"761_CR3","doi-asserted-by":"crossref","first-page":"12S","DOI":"10.1016\/S0002-9343(97)90022-X","volume":"1103","author":"C Cooper","year":"1997","unstructured":"Cooper C (1997) The crippling consequences of fractures and their impact on quality of life. Am J Med 1103(2A):12S\u201317S discussion 17S-19S","journal-title":"Am J Med"},{"issue":"12","key":"761_CR4","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","volume":"17","author":"O Johnell","year":"2006","unstructured":"Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17(12):1726\u20131733","journal-title":"Osteoporos Int"},{"key":"761_CR5","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","volume":"23","author":"F Saad","year":"2012","unstructured":"Saad F, Brown JE, Van Poznak C et al (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23:1341\u20131347","journal-title":"Ann Oncol"},{"issue":"7","key":"761_CR6","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1210\/jc.2012-1027","volume":"97","author":"S Khosla","year":"2012","unstructured":"Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM et al (2012) Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab 97(7):2272\u20132282","journal-title":"J Clin Endocrinol Metab"},{"key":"761_CR7","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung M, Siris ES, Eastell R, Reid IR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"761_CR8","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: Results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513\u2013523","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"32","key":"761_CR9","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.2174\/1381612033453640","volume":"9","author":"MJ Rogers","year":"2003","unstructured":"Rogers MJ (2003) New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9(32):2643\u20132658","journal-title":"Curr Pharm Des"},{"issue":"Suppl 1","key":"761_CR10","first-page":"S293","volume":"20","author":"MC Peterson","year":"2005","unstructured":"Peterson MC, Stouch BJ, Martin SW et al (2005) The pharmacokinetics of denosumab (AMG 162) following various multiple subcutaneous dosing regimens in postmenopausal women with low bone mass. J Bone Miner Res 20(Suppl 1):S293","journal-title":"J Bone Miner Res"},{"issue":"4","key":"761_CR11","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","volume":"48","author":"R Baron","year":"2011","unstructured":"Baron R, Ferrari S, Russell RG (2011) Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48(4):677\u2013692","journal-title":"Bone"},{"issue":"2","key":"761_CR12","doi-asserted-by":"crossref","first-page":"70","DOI":"10.11622\/smedj.2018014","volume":"259","author":"BH Chan","year":"2018","unstructured":"Chan BH, Yee R, Puvanendran R, Ang SB (2018) Medication-related osteonecrosis of the jaw in osteoporotic patients: prevention and management. Singap Med J 259(2):70\u201375","journal-title":"Singap Med J"},{"issue":"10","key":"761_CR13","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","volume":"22","author":"S Khosla","year":"2007","unstructured":"Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D et al (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22(10):1479\u20131491","journal-title":"J Bone Miner Res"},{"key":"761_CR14","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J et al (2014) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws 2014 update. J Oral Maxillofac Surg 72:1938\u20131956","journal-title":"J Oral Maxillofac Surg"},{"issue":"7","key":"761_CR15","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.joms.2008.02.012","volume":"66","author":"L Junquera","year":"2008","unstructured":"Junquera L, Gallego L (2008) Nonexposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant? J Oral Maxillofac Surg 66(7):1516\u20131517","journal-title":"J Oral Maxillofac Surg"},{"issue":"6","key":"761_CR16","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3174\/ajnr.A0518","volume":"28","author":"PM Phal","year":"2007","unstructured":"Phal PM, Myall RW, Assael LA, Weissman JL (2007) Imaging findings of bisphosphonate-associated osteonecrosis of the jaws. AJNR Am J Neuroradiol 28(6):1139\u20131145","journal-title":"AJNR Am J Neuroradiol"},{"issue":"4","key":"761_CR17","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.coms.2015.06.001","volume":"27","author":"T Aghaloo","year":"2015","unstructured":"Aghaloo T, Hazboun R, Tetradis S (2015) Pathophysiology of osteonecrosis of the jaws. Oral Maxillofac Surg Clin North Am 27(4):489\u2013496","journal-title":"Oral Maxillofac Surg Clin North Am"},{"issue":"5","key":"761_CR18","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s11914-018-0474-4","volume":"16","author":"J Chang","year":"2018","unstructured":"Chang J, Hakam AE, McCauley LK (2018) Current understanding of the pathophysiology of osteonecrosis of the jaw. Curr Osteoporos Rep 16(5):584\u2013595","journal-title":"Curr Osteoporos Rep"},{"key":"761_CR19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11926-008-0018-5","volume":"10","author":"PN Sambrook","year":"2008","unstructured":"Sambrook PN, Ebeling P (2008) Osteonecrosis of the jaw. Curr Rheumatol Rep 10:97\u2013101","journal-title":"Curr Rheumatol Rep"},{"key":"761_CR20","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1634\/theoncologist.2011-0202","volume":"17","author":"P Nicoletti","year":"2012","unstructured":"Nicoletti P, Cartsos VM, Palaska PK et al (2012) Genome wide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3. Oncologist 17:279","journal-title":"Oncologist"},{"key":"761_CR21","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000342120","volume":"129","author":"D-N Zhong","year":"2013","unstructured":"Zhong D-N, Wu J-Z, Li G-J (2013) Association between CYP2C8 (rs1934951) polymorphism and bisphosphonate-related osteonecrosis of the jaws in patients on bisphosphonate therapy: a meta-analysis. Acta Haematol 129:90\u201395","journal-title":"Acta Haematol"},{"key":"761_CR22","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.amjmed.2008.12.005","volume":"122","author":"SL Silverman","year":"2009","unstructured":"Silverman SL, Landesberg R (2009) Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med 122:S33\u2013S45","journal-title":"Am J Med"},{"issue":"3","key":"761_CR23","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1747-4477.2009.00213.x","volume":"35","author":"SL Ruggiero","year":"2009","unstructured":"Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B (2009) Task force on bisphosphonate-related osteonecrosis of the jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. Aust Endod J 35(3):119\u2013130","journal-title":"Aust Endod J"},{"issue":"2","key":"761_CR24","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2217\/fon.13.211","volume":"10","author":"G Campisi","year":"2014","unstructured":"Campisi G, Fedele S, Fusco V, Pizzo G, Di Fede O, Bedogni A (2014) Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents. Future Oncol 10(2):257\u2013275","journal-title":"Future Oncol"},{"issue":"2","key":"761_CR25","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/jbmr.2693","volume":"31","author":"X Zhang","year":"2016","unstructured":"Zhang X, Hamadeh IS, Song S, Katz J, Moreb JS, Langaee TY et al (2016) Osteonecrosis of the jaw in the United States Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS). J Bone Miner Res 31(2):336\u2013340","journal-title":"J Bone Miner Res"},{"issue":"11","key":"761_CR26","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1634\/theoncologist.2009-0115","volume":"14","author":"PK Palaska","year":"2009","unstructured":"Palaska PK, Cartsos V, Zavras AI (2009) Bisphosphonates and time to osteonecrosis development. Oncologist. 14(11):1154\u20131166","journal-title":"Oncologist."},{"issue":"17","key":"761_CR27","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.2146\/ajhp080251","volume":"66","author":"SN Gebara","year":"2009","unstructured":"Gebara SN, Moubayed H (2009) Risk of osteonecrosis of the jaw in cancer patients taking bisphosphonates. Am J Health Syst Pharm 66(17):1541\u20131547","journal-title":"Am J Health Syst Pharm"},{"key":"761_CR28","doi-asserted-by":"publisher","first-page":"215034","DOI":"10.1155\/2013\/215034","volume":"2013","author":"I Coskun Benlidayi","year":"2013","unstructured":"Coskun Benlidayi I, Guzel R (2013) Oral bisphosphonate related osteonecrosis of the jaw: a challenging adverse effect. ISRN Rheumatol 2013:215034. https:\/\/doi.org\/10.1155\/2013\/215034","journal-title":"ISRN Rheumatol"},{"issue":"6","key":"761_CR29","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jcms.2015.03.039","volume":"43","author":"S Otto","year":"2015","unstructured":"Otto S, Tr\u00f6ltzsch M, Jambrovic V, Panya S, Probst F, Ristow O et al (2015) Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: a trigger for BRONJ development? J Craniomaxillofac Surg 43(6):847\u2013854","journal-title":"J Craniomaxillofac Surg"},{"issue":"4","key":"761_CR30","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/odi.12447","volume":"22","author":"J Bagan","year":"2016","unstructured":"Bagan J, Peydr\u00f3 A, Calvo J, Leopoldo M, Jim\u00e9nez Y, Bagan L (2016) Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis. Oral Dis 22(4):324\u2013329","journal-title":"Oral Dis"},{"issue":"2","key":"761_CR31","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00520-018-4501-x","volume":"27","author":"O Nicolatou-Galitis","year":"2018","unstructured":"Nicolatou-Galitis O, Kouri M, Papadopoulou E, Vardas E, Galiti D, Epstein JB, Elad S, Campisi G, Tsoukalas N, Bektas-Kayhan K, Tan W, Body JJ, Migliorati C, Lalla RV (2018) MASCC Bone Study Group. Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. Support Care Cancer 27(2):383\u2013394","journal-title":"Support Care Cancer"},{"key":"761_CR32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.oraloncology.2018.08.003","volume":"85","author":"H Karna","year":"2018","unstructured":"Karna H, Gonzalez J, Radia HS, Sedghizadeh PP, Enciso R (2018) Risk-reductive dental strategies for medication related osteonecrosis of the jaw among cancer patients: a systematic review with meta-analyses. Oral Oncol 85:15\u201323","journal-title":"Oral Oncol"},{"issue":"2","key":"761_CR33","first-page":"72","volume":"11","author":"MA Nazir","year":"2017","unstructured":"Nazir MA (2017) Prevalence of periodontal disease, its association with systemic diseases and prevention. Int J Health Sci (Qassim) 11(2):72\u201380","journal-title":"Int J Health Sci (Qassim)"},{"issue":"1","key":"761_CR34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jpor.2014.08.001","volume":"59","author":"K Niibe","year":"2015","unstructured":"Niibe K et al (2015) Osteonecrosis of the jaw in patients with dental prostheses being treated with bisphosphonates or denosumab. J Prosthodontic Res 59(1):3\u20135","journal-title":"J Prosthodontic Res"},{"issue":"32","key":"761_CR35","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1200\/JCO.2009.21.9584","volume":"27","author":"K Vahtsevanos","year":"2009","unstructured":"Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG et al (2009) Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 27(32):5356\u20135362","journal-title":"J Clin Oncol"},{"issue":"1","key":"761_CR36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jcms.2012.10.018","volume":"41","author":"P Stockmann","year":"2013","unstructured":"Stockmann P, Nkenke E, Englbrecht M, Schlittenbauer T, Wehrhan F, Rauh C et al (2013) Major histocompatibility complex class II polymorphisms are associated with the development of anti-resorptive agent-induced osteonecrosis of the jaw. J Craniomaxillofac Surg 41(1):71\u201375","journal-title":"J Craniomaxillofac Surg"},{"issue":"4","key":"761_CR37","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1517\/17425255.2016.1154533","volume":"12","author":"L L\u00f3pez-Delgado","year":"2016","unstructured":"L\u00f3pez-Delgado L, Riancho-Zarrabeitia L, Riancho JA (2016) Genetic and acquired factors influencing the effectiveness and toxicity of drug therapy in osteoporosis. Expert Opin Drug Metab Toxicol 12(4):389\u2013398","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"761_CR38","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","volume":"62","author":"SL Ruggiero","year":"2004","unstructured":"Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62(5):527\u2013534","journal-title":"J Oral Maxillofac Surg"},{"issue":"34","key":"761_CR39","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","volume":"23","author":"A Bamias","year":"2005","unstructured":"Bamias A, Kastritis E, Bamia C et al (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23(34):8580\u20138587","journal-title":"J Clin Oncol"},{"key":"761_CR40","doi-asserted-by":"crossref","first-page":"151","DOI":"10.11005\/jbm.2015.22.4.151","volume":"22","author":"KM Kim","year":"2015","unstructured":"Kim KM, Rhee Y, Kwon YD, Kwon TG, Lee JK, Kim DY (2015) Medication related osteonecrosis of the jaw: 2015 position statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons. J Bone Metab 22:151\u2013165","journal-title":"J Bone Metab"},{"issue":"18","key":"761_CR41","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809\u20131822","journal-title":"N Engl J Med"},{"issue":"11","key":"761_CR42","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.14219\/jada.archive.2010.0082","volume":"141","author":"JT Grbic","year":"2011","unstructured":"Grbic JT, Black DM, Lyles KW, Reid DM, Orwoll E, McClung M et al (2011) The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. J Am Dent Assoc 141(11):1365\u20131370","journal-title":"J Am Dent Assoc"},{"issue":"1","key":"761_CR43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK et al (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30(1):3\u201323","journal-title":"J Bone Miner Res"},{"issue":"6","key":"761_CR44","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1210\/jc.2010-2784","volume":"96","author":"S Boonen","year":"2011","unstructured":"Boonen S, Adachi JD, Man Z, Cummings SR, Lippuner K, T\u00f6rring O et al (2011) Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 96(6):1727\u20131736","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"761_CR45","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","volume":"26","author":"S Papapoulos","year":"2015","unstructured":"Papapoulos S, Lippuner K, Roux C, Lin CJ, Kendler DL, Lewiecki EM (2015) The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int 26(12):2773\u20132783","journal-title":"Osteoporos Int"},{"issue":"2","key":"761_CR46","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4103\/2231-0762.178742","volume":"6","author":"D Rosella","year":"2016","unstructured":"Rosella D, Papi P, Giardino R, Cicalini E, Piccoli L, Pompa G (2016) Medication-related osteonecrosis of the jaw: clinical and practical guidelines. J Int Soc Prev Community Dent 6(2):97\u2013104","journal-title":"J Int Soc Prev Community Dent"},{"key":"761_CR47","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1749-6632.2010.05771.x","volume":"1218","author":"AO Hoff","year":"2011","unstructured":"Hoff AO, Toth B, Hu M, Hortobagyi GN, Gagel RF (2011) Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Ann N Y Acad Sci 1218:47\u201354","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"761_CR48","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/0022034510397196","volume":"90","author":"J Barasch","year":"2011","unstructured":"Barasch J, Cunha-Cruz FA, Curro P, Hujoel AH, Sung D, Vena AE, Voinea-Griffin, the CONDOR Collaborative Group\u2020 (2011) Risk factors for osteonecrosis of the jaws a case-control study from the CONDOR dental PBRN. J Dent Res 90(4):439\u2013444","journal-title":"J Dent Res"},{"key":"761_CR49","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1210\/jc.2013-1597","volume":"98","author":"HG Bone","year":"2013","unstructured":"Bone HG, Chapurlat R, Brandi M-L et al (2013) The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab 98:4483\u20134492","journal-title":"J Clin Endocrinol Metab"},{"key":"761_CR50","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","volume":"76","author":"C Christodoulou","year":"2009","unstructured":"Christodoulou C, Pervena A, Klouvas G et al (2009) Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 76:209\u2013211","journal-title":"Oncology"},{"issue":"1","key":"761_CR51","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S1470-2045(13)70539-4","volume":"15","author":"P Barrett-Lee","year":"2014","unstructured":"Barrett-Lee P, Casbard A, Abraham J, Hood K, Coleman R, Simmonds P, Timmins H et al (2014) Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. Lancet Oncol 15(1):114\u2013122","journal-title":"Lancet Oncol"},{"key":"761_CR52","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/JTO.0b013e31826aec2b","volume":"7","author":"GV Scagliotti","year":"2012","unstructured":"Scagliotti GV, Hirsh V, Siena S et al (2012) Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol 7:1823","journal-title":"J Thorac Oncol"},{"issue":"7","key":"761_CR53","first-page":"968","volume":"91","author":"MA Dimopoulos","year":"2006","unstructured":"Dimopoulos MA, Kastritis E, Anagnostopoulos A et al (2006) Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 91(7):968\u2013971","journal-title":"Haematologica"},{"issue":"4","key":"761_CR54","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.coms.2015.06.003","volume":"27","author":"TB Dodson","year":"2015","unstructured":"Dodson TB (2015) The frequency of medication-related osteonecrosis of the jaw and its associated risk factors. Oral Maxillofac Surg Clin North Am 27(4):509\u2013516","journal-title":"Oral Maxillofac Surg Clin North Am"},{"issue":"12","key":"761_CR55","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1248\/bpb.b15-00385","volume":"38","author":"M Kajizono","year":"2015","unstructured":"Kajizono M, Sada H, Sugiura Y, Soga Y, Kitamura Y, Matsuoka J, Sendo T (2015) Incidence and risk factors of osteonecrosis of the jaw in advanced cancer patients after treatment with zoledronic acid or denosumab: a retrospective cohort study. Biol Pharm Bull 38(12):1850\u20131855","journal-title":"Biol Pharm Bull"},{"key":"761_CR56","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00520-010-0882-1","volume":"18","author":"CA Migliorati","year":"2010","unstructured":"Migliorati CA, Woo SB, Hewson I, Barasch A, Elting LS, Spijkervet FK, Brennan MT (2010) Bisphosphonate Osteonecrosis Section, Oral Care Study Group, Multinational Association of Supportive Care in Cancer (MASCC)\/International Society of Oral Oncology (ISOO). A systematic review of bisphosphonate osteonecrosis (BON) in cancer. Support. Care Cancer 18:1099\u20131106","journal-title":"Care Cancer"},{"issue":"1","key":"761_CR57","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.bjorl.2017.05.008","volume":"84","author":"GH Ribeiro","year":"2018","unstructured":"Ribeiro GH, Chrun ES, Dutra KL, Daniel FI, Grando LJ (2018) Osteonecrosis of the jaws: a review and update in etiology and treatment. Braz J Otorhinolaryngol 84(1):102\u2013108","journal-title":"Braz J Otorhinolaryngol"},{"issue":"3","key":"761_CR58","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s12663-014-0707-8","volume":"14","author":"GD Rabelo","year":"2014","unstructured":"Rabelo GD, Assun\u00e7\u00e3o JN, Chavassieux P, Soares HA, Alves FA, Lemos CA (2014) Bisphosphonate-related osteonecrosis of the jaws and its array of manifestations. J Maxillofac Oral Surg 14(3):699\u2013705","journal-title":"J Maxillofac Oral Surg"},{"issue":"1","key":"761_CR59","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40729-016-0041-7","volume":"2","author":"C Walter","year":"2016","unstructured":"Walter C, Al-Nawas B, Wolff T, Schiegnitz E, Gr\u00f6tz KA (2016) Dental implants in patients treated with antiresorptive medication - a systematic literature review. Int J Implant Dent 2(1):9","journal-title":"Int J Implant Dent"},{"issue":"10","key":"761_CR60","doi-asserted-by":"crossref","first-page":"1937.e1","DOI":"10.1016\/j.joms.2014.04.037","volume":"72","author":"D Holzinger","year":"2014","unstructured":"Holzinger D, Seemann R, Matoni N, Ewers R, Millesi W, Wutzl A (2014) Effect of dental implants on bisphosphonates related osteonecrosis of the jaws. J Oral Maxillofac Surg 72(10):1937.e1","journal-title":"J Oral Maxillofac Surg"},{"issue":"1","key":"761_CR61","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00784-012-0708-2","volume":"17","author":"C Jacobsen","year":"2013","unstructured":"Jacobsen C, Metzler P, R\u00f6ssle M, Obwegeser J, Zemann W, Gr\u00e4tz K (2013) Osteopathology induced by bisphosphonates and dental implants: clinical observation. Clin Oral Investig 17(1):167\u2013175","journal-title":"Clin Oral Investig"},{"issue":"2","key":"761_CR62","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/clr.12526","volume":"27","author":"J Ata-Ali","year":"2014","unstructured":"Ata-Ali J, Ata-Ali F, Pe\u00f1arrocha-Oltra D, Galindo-Moreno P (2014) What is the impact of bisphosphonate therapy upon dental implant survival? A systematic review and meta-analysis. Clin Oral Implants Res 27(2):38\u201346","journal-title":"Clin Oral Implants Res"},{"issue":"3","key":"761_CR63","first-page":"328","volume":"24","author":"M Alsabbagh","year":"2015","unstructured":"Alsabbagh M, Robinson F, Romanos G, Thomas M (2015) Osteoporosis and bisphosphonate-related osteonecrosis in a dental school implant patient population. Implant Dent 24(3):328\u2013332","journal-title":"Implant Dent"},{"issue":"5","key":"761_CR64","first-page":"63","volume":"114","author":"P Poxleitner","year":"2017","unstructured":"Poxleitner P, Engelhardt M, Schmelzeisen R, Voss P (2017) The prevention of medication-related osteonecrosis of the jaw. Dtsch Arztebl Int 114(5):63\u201369","journal-title":"Dtsch Arztebl Int"},{"issue":"8","key":"761_CR65","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1007\/s00198-017-4063-7","volume":"28","author":"T Hasegawa","year":"2017","unstructured":"Hasegawa T, Kawakita A, Ueda N, Funahara R, Tachibana A, Kobayashi et al (2017) A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ? Osteoporos Int 28(8):2465\u20132473","journal-title":"Osteoporos Int"},{"key":"761_CR66","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/annonc\/mdn526","volume":"20","author":"CI Ripamonti","year":"2009","unstructured":"Ripamonti CI, Maniezzo M, Campa T et al (2009) Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20:137\u2013145","journal-title":"Ann Oncol"},{"key":"761_CR67","first-page":"593","volume":"59","author":"S Ferlito","year":"2010","unstructured":"Ferlito S, Liardo C, Puzzo S (2010) Dental extractions in patient treated with intravenous bisphosphonates and risk of osteonecrosis of jaws: presentation of a preventive protocol and case series. Minerva Stomatol 59:593\u2013601","journal-title":"Minerva Stomatol"},{"key":"761_CR68","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.amjmed.2012.06.023","volume":"126","author":"M McClung","year":"2013","unstructured":"McClung M, Harris ST, Miller PD et al (2013) Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 126:13\u201320","journal-title":"Am J Med"},{"key":"761_CR69","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.joms.2006.11.003","volume":"65","author":"Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws","year":"2007","unstructured":"Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws (2007) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65:369\u2013376","journal-title":"J Oral Maxillofac Surg"},{"key":"761_CR70","unstructured":"Scottish Dental Clinical Effectiveness Programme. (2017) Oral health management of patients at risk of medication-related osteonecrosis of the jaw. http:\/\/www.nice.org.uk\/accreditation"},{"issue":"2","key":"761_CR71","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jcms.2016.12.010","volume":"45","author":"M Zandi","year":"2017","unstructured":"Zandi M, Dehghan A, Mohammadi-Mofrad A, Amini P, Vahdatinia F (2017) Short-term perioperative teriparatide therapy for the prevention of medication-related osteonecrosis of the jaw: A randomized, controlled preclinical study in rats. J Craniomaxillofac Surg 45(2):275\u2013228","journal-title":"J Craniomaxillofac Surg"},{"issue":"588-589","key":"761_CR72","first-page":"81","volume":"14","author":"F Livio","year":"2018","unstructured":"Livio F (2018) Pharmacovigilance update. Rev Med Suisse 14(588-589):81\u201384","journal-title":"Rev Med Suisse"},{"key":"761_CR73","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.joms.2007.08.003","volume":"65","author":"RE Marx","year":"2007","unstructured":"Marx RE, Cillo JE Jr, Ulloa JJ (2007) Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65:2397\u20132410","journal-title":"J Oral Maxillofac Surg"},{"key":"761_CR74","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s10103-011-0974-2","volume":"26","author":"B Atalay","year":"2011","unstructured":"Atalay B, Yalcin S, Emes Y et al (2011) Bisphosphonate-related osteonecrosis: laser-assisted surgical treatment or conventional surgery? Lasers Med Sci 26:815\u2013823","journal-title":"Lasers Med Sci"},{"key":"761_CR75","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.joms.2009.02.004","volume":"67","author":"R Kunchur","year":"2009","unstructured":"Kunchur R, Need A, Hughes T, Goss A (2009) Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg 67:1167\u20131173","journal-title":"J Oral Maxillofac Surg"},{"key":"761_CR76","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/ID.0b013e3181cec8bc","volume":"19","author":"CY Lee","year":"2010","unstructured":"Lee CY, Suzuki JB (2010) CTX biochemical marker of bone a reliable predictor of bisphosphonate-associated osteonecrosis of metabolism. Is it the jaws after surgery? Part II: a prospective clinical study. Implant Dent 19:29\u201338","journal-title":"Implant Dent"},{"key":"761_CR77","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s11845-011-0790-5","volume":"181","author":"JE O\u2019Connell","year":"2012","unstructured":"O\u2019Connell JE, Ikeagwani O, Kearns GJ (2012) A role for C-terminal crosslinking telopeptide (CTX) level to predict the development of bisphosphonate-related osteonecrosis of the jaws (BRONJ) following oral surgery? Ir J Med Sci 181:237\u2013242","journal-title":"Ir J Med Sci"},{"issue":"5","key":"761_CR78","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/AOG.0b013e3181bdce0a","volume":"114","author":"M McClung","year":"2009","unstructured":"McClung M, Miller P, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou CL (2009) Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. Obstet Gynecol 114(5):999\u20131007","journal-title":"Obstet Gynecol"},{"key":"761_CR79","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.joms.2011.12.028","volume":"70","author":"PG Morris","year":"2012","unstructured":"Morris PG, Fazio M, Farooki A et al (2012) Serum N-telopeptide and bone specific alkaline phosphatase levels in patients with osteonecrosis of the jaw receiving bisphosphonates for bone metastases. J Oral Maxillofac Surg 70:2768\u20132775","journal-title":"J Oral Maxillofac Surg"},{"key":"761_CR80","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.joms.2008.09.015","volume":"67","author":"S Lehrer","year":"2009","unstructured":"Lehrer S, Montazem A, Ramanathan L et al (2009) Bisphosphonate induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene. J Oral Maxillofac Surg 67:159\u2013161","journal-title":"J Oral Maxillofac Surg"},{"key":"761_CR81","unstructured":"Medina A, Rosero O, Rueda PN, S\u00e1nchez F, Chalem M, Gonz\u00e1lez MA et al. (2018) II Consenso Colombiano para el manejo de la osteoporosis posmenop\u00e1usica. Rev Colomb Reumatol"},{"key":"761_CR82","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s00223-014-9842-y","volume":"94","author":"H Johansson","year":"2014","unstructured":"Johansson H, Oden A, Kanis JA et al (2014) A meta-analysis of reference markers of bone turnover for prediction of fracture. Calcif Tissue Int 94:560\u2013567","journal-title":"Calcif Tissue Int"},{"issue":"12","key":"761_CR83","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.ijom.2015.07.018","volume":"44","author":"H Kakehashi","year":"2015","unstructured":"Kakehashi H, Ando T, Minamizato T, Nakatani Y, Kawasaki T, Ikeda H et al (2015) Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw: preliminary findings. Int J Oral Maxillofac Surg 44(12):1558\u20131564","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"1-2","key":"761_CR84","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/odi.12783","volume":"24","author":"H Kagami","year":"2018","unstructured":"Kagami H, Inoue M, Kobayashi A, Taguchi A, Li X, Yoshizawa M (2018) Issues with the surgical treatment of antiresorptive agent-related osteonecrosis of the jaws. Oral Dis 24(1-2):52\u201356","journal-title":"Oral Dis"},{"issue":"7","key":"761_CR85","doi-asserted-by":"crossref","first-page":"e575","DOI":"10.1097\/SCS.0000000000002127","volume":"26","author":"E Yamachika","year":"2015","unstructured":"Yamachika E, Matsubara M, Ikeda A, Matsumura T, Moritani N, Iida ST (2015) Treatment of osteonecrosis of the jaw. J Craniofac Surg 26(7):e575\u2013e577","journal-title":"J Craniofac Surg"},{"issue":"1","key":"761_CR86","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jocd.2016.09.005","volume":"20","author":"AA Khan","year":"2017","unstructured":"Khan AA, Morrison A, Kendler DL, Rizzoli R, Hanley DA, Felsenberg D et al (2017) Case-Based review of osteonecrosis of the jaw (ONJ) and application of the International Recommendations for Management from the International Task Force on ONJ. J Clin Densitom 20(1):8\u201324","journal-title":"J Clin Densitom"},{"key":"761_CR87","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","volume":"122","author":"V Guarneri","year":"2010","unstructured":"Guarneri V, Miles D, Robert N et al (2010) Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 122:181","journal-title":"Breast Cancer Res Treat"},{"key":"761_CR88","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1532-3382(12)70046-5","volume":"12","author":"J Yamashita","year":"2012","unstructured":"Yamashita J, McCauley LK (2012) Antiresorptives and osteonecrosis of the jaw. J Evid Based Dent Pract 12:233","journal-title":"J Evid Based Dent Pract"},{"key":"761_CR89","first-page":"b147","volume":"77","author":"R Bonacina","year":"2011","unstructured":"Bonacina R, Mariani U, Villa F et al (2011) Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients. J Can Dent Assoc 77:b147","journal-title":"J Can Dent Assoc"},{"key":"761_CR90","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.joms.2009.03.050","volume":"68","author":"JC Lo","year":"2010","unstructured":"Lo JC, O\u2019Ryan FS (2010) Gordon NP, et al: (2010) Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 68:243","journal-title":"J Oral Maxillofac Surg"},{"key":"761_CR91","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.08.003","volume":"105","author":"E Tsourdi","year":"2017","unstructured":"Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Gua\u00f1abens N et al (2017) Discontinuation of Denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 105:11\u201317. https:\/\/doi.org\/10.1016\/j.bone.08.003","journal-title":"Bone"},{"issue":"6","key":"761_CR92","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jamainternmed.2015.0747","volume":"175","author":"S Greenspan","year":"2015","unstructured":"Greenspan S, Perera S, Ferchak MA, Nace D, Resnick N (2015) Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical Trial. JAMA Intern Med 175(6):913\u2013921","journal-title":"JAMA Intern Med"},{"issue":"6","key":"761_CR93","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.bone.2012.03.016","volume":"50","author":"A Grey","year":"2012","unstructured":"Grey A, Bolland MJ, Horne A, Wattie D, House M, Gamble G, Reid IR (2012) Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial. Bone. 50(6):1389\u20131393","journal-title":"Bone."},{"key":"761_CR94","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, Costa L (2011) Goldwasser F, et al: (2006) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125","journal-title":"J Clin Oncol"},{"key":"761_CR95","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.4065\/81.8.1100","volume":"81","author":"D Kademani","year":"2006","unstructured":"Kademani D, Koka S, Lacy MQ et al (2006) Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy. Mayo Clin Proc 81:1100","journal-title":"Mayo Clin Proc"},{"key":"761_CR96","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.amjmed.2010.04.033","volume":"123","author":"S Fedele","year":"2010","unstructured":"Fedele S, Porter SR, D\u2019Aiuto F et al (2010) Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med 123:1060","journal-title":"Am J Med"},{"key":"761_CR97","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.archoralbio.2014.05.002","volume":"59","author":"C Boff","year":"2014","unstructured":"Boff C, Salum FG, Figueredo MA, Cherubini K (2014) Important aspects regarding the role of microorganisms in bisphosphonates-related osteonecrosis of the jaw. Arch Oral Biol 59:790\u2013799","journal-title":"Arch Oral Biol"},{"key":"761_CR98","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/adj.12217","volume":"59","author":"M O\u2019Halloran","year":"2014","unstructured":"O\u2019Halloran M, Boyd NM, Smith A (2014) Denosumab and osteonecrosis of the jaws\u2013the pharmacology, pathogenesis and a report of two cases. Aust Dent J 59:516\u2013519","journal-title":"Aust Dent J"},{"issue":"4","key":"761_CR99","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.joms.2015.09.028","volume":"74","author":"V Thumbigere-Math","year":"2015","unstructured":"Thumbigere-Math V, Michalowicz BS, Hughes PJ et al (2015) Serum markers of bone turnover and angiogenesis in patients with bisphosphonate-related osteonecrosis of the jaw after discontinuation of long-term intravenous bisphosphonate therapy. J Oral Maxillofac Surg 74(4):738\u2013746","journal-title":"J Oral Maxillofac Surg"},{"issue":"1","key":"761_CR100","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/sj.bdj.2017.573","volume":"223","author":"M Badr","year":"2017","unstructured":"Badr M, Kyriakidou E, Atkins A, Harrison S (2017) Aggressive denosumab-related jaw necrosis - a case series. Br Dent J 223(1):13\u201316","journal-title":"Br Dent J"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-020-00761-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-020-00761-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-020-00761-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T20:02:20Z","timestamp":1625342540000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-020-00761-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,4]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["761"],"URL":"https:\/\/doi.org\/10.1007\/s11657-020-00761-0","relation":{},"ISSN":["1862-3522","1862-3514"],"issn-type":[{"value":"1862-3522","type":"print"},{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,4]]},"assertion":[{"value":"13 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"101"}}